ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Arima Genomics is Enabling Single Cell 3D Genome Exploration of the Human Brain, One Cell at a Time

Arima Genomics, Inc., the leader in 3D genomics, today announced that it is launching into the world of single-cell analyses by enabling a team of researchers to map the 3D genome of the human brain, cell by cell. The work is being carried out at multiple institutions including the Salk Institute, and the University of California, Los Angeles, under the umbrella of The BRAIN Initiative Cell Atlas Network (BICAN) and the Brain Research Through Advancing Innovative Neurotechnologies (BRAIN) Initiative.

The research spans several multi-omic technologies, including 3D genomics, DNA methylation and RNA expression, to describe brain cells in unprecedented molecular detail – to classify brain cells into precise subtypes and pinpoint the location of each brain cell. Specifically, they will use the Arima Genomics kits as part of their single-nucleus methyl-3C sequencing ​(sn-m3C-Seq) workflow, which enables concurrent cell-by-cell interrogation of the methylation state and 3D chromatin organization of the genome.

“Applying 3D genomic technologies at the single-cell level is an incredibly powerful approach. We are just beginning to understand its potential to reveal new biology in the brain,” said Anthony Schmitt, PhD, Senior Vice President of Science at Arima Genomics. “We are thrilled to partner with the multidisciplinary teams to maximize the impact of this critical research into the genetics of human brain function and aging.”

Using this single-cell 3D genomics approach, the team aims to better understand how neurotypical human brains develop, work, and age, helping to establish a baseline against which scientists can compare brains with neurological or psychiatric conditions, including Alzheimer’s disease, autism, depression, and traumatic brain injury. In addition, through differentiation between cell types in the brain, the researchers aim to resolve unique gene regulation programs and cellular mechanisms that determine functional changes in aging and disease that may be vulnerable to therapeutic intervention.

“Single-cell multi-omics including the 3D genomics approach allows us to peek into the inner workings of the human genome, as they can be used to explain the genetic programs that lead to vastly different morphology and function of cell types, tissues, and organs,” said Chongyuan Luo, PhD, Assistant Professor, David Geffen School of Medicine, UCLA. “The single-cell data generated from this project will help us create a comprehensive map of the gene regulatory landscape of human brain development, helping point scientists in the right direction as they aim to understand the genetic causes of neurological and psychiatric conditions, and how to best treat them.”

To learn more about single-cell 3D genomics, watch the recording of our webinar entitled Single-Cell 3D Genomics in Neuroscience and the BRAIN Initiative.

About Arima Genomics

Arima Genomics, Inc. is advancing life sciences research through the power of 3D genomics by providing unparalleled access to the sequence and structure of any genome. Arima Genomics offers the most advanced technologies for preserving the structural organization of the genome to drive discovery in genome biology and human health. To learn more, visit www.arimagenomics.com and connect with us on Twitter, LinkedIn, and YouTube.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  244.41
+0.00 (0.00%)
AAPL  268.47
+0.00 (0.00%)
AMD  233.54
+0.00 (0.00%)
BAC  53.20
+0.00 (0.00%)
GOOG  279.70
+0.00 (0.00%)
META  621.71
+0.00 (0.00%)
MSFT  496.82
+0.00 (0.00%)
NVDA  188.15
+0.00 (0.00%)
ORCL  239.26
+0.00 (0.00%)
TSLA  429.52
+0.00 (0.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.